Golimumab
Tumor Necrosis Factor Alpha (Tnf-Alpha) Inhibitors
Sold as Simponi · Gotenfia · GOBIVAZ · LIVMOTY · UPGOLYV
- Drug class
- Tumor Necrosis Factor Alpha (Tnf-Alpha) Inhibitors
- Availability
- See label
- Routes
- Subcutaneous, Intravenous
- Markets covered
- 3
- Products on record
- 38
Overview
Golimumab is an active pharmaceutical ingredient in the Tumor Necrosis Factor Alpha (Tnf-Alpha) Inhibitors group (L04AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 22 | May 22, 2026 |
| EU European Union | EMA | 3 | March 5, 2026 |
| CA Canada | Health Canada | 13 | May 22, 2026 |
GBUnited Kingdom· MHRA
22 products
Uses
Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.
• the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) GOBIVAZ in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.
Psoriatic arthritis (PsA) GOBIVAZ, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. 1) and to improve physical function.
EUEuropean Union· EMA
3 products
Uses
Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with MTX.
Ulcerative colitis Paediatric ulcerative colitis (pUC) Simponi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients 2 years of age and older with a body weight of at least 15 kg, who have had an inadequate response to conventional therapy, including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
How to take
CACanada· Health Canada
13 products
13 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Golimumab. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 306. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL567340024 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/000992 · revised March 5, 2026
- [3]Health Canada (DPD) · 02324776 · revised May 6, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.